2.84
+0.08(+2.90%)
Currency In USD
| Previous Close | 2.76 |
| Open | 2.8 |
| Day High | 2.94 |
| Day Low | 2.8 |
| 52-Week High | 5.54 |
| 52-Week Low | 2.32 |
| Volume | 1M |
| Average Volume | 877,301 |
| Market Cap | 170.06M |
| PE | 4.37 |
| EPS | 0.65 |
| Moving Average 50 Days | 2.71 |
| Moving Average 200 Days | 3.38 |
| Change | 0.08 |
If you invested $1000 in Eledon Pharmaceuticals, Inc. (ELDN) 10 years ago, it would be worth $1.55 as of October 04, 2025 at a share price of $2.84. Whereas If you bought $1000 worth of Eledon Pharmaceuticals, Inc. (ELDN) shares 5 years ago, it would be worth $154.94 as of October 04, 2025 at a share price of $2.84.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Eledon Pharmaceuticals to Present at the 18th Congress of the International Xenotransplantation Association
GlobeNewswire Inc.
Sep 24, 2025 8:05 PM GMT
IRVINE, Calif., Sept. 24, 2025 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today announced that Steve Perrin, Ph.D., President and Chief Scientific Officer, will participate in a plenary session at the upcoming 18th C
Eledon Pharmaceuticals to Participate in Cantor Global Healthcare Conference 2025
GlobeNewswire Inc.
Aug 29, 2025 11:00 AM GMT
IRVINE, Calif., Aug. 29, 2025 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today announced that David-Alexandre C. Gros, M.D., Chief Executive Officer, will participate in a fireside chat at the upcoming Cantor Global
Eledon Presents Updated Data from Ongoing Phase 1b Trial Evaluating Tegoprubart for Prevention of Rejection in Kidney Transplantation
GlobeNewswire Inc.
Aug 06, 2025 8:01 PM GMT
Data from patients who remained on tegoprubart for a year showed overall mean 12-month eGFR of approximately 68 mL/min/1.73 m² post-transplant Preliminary iBox data, a key biomarker of kidney function and immunologic response, supports that tegopruba